New cocktail therapy takes on tough pancreatic cancer
NCT ID NCT06951997
First seen Jan 29, 2026 · Last updated May 14, 2026 · Updated 17 times
Summary
This study tests a mix of four drugs (iparomlimab, tuvonralimab, chidamide, and chemotherapy) as a first treatment for people with metastatic pancreatic cancer that has spread. The goal is to see if the combination can shrink tumors and help people live longer. The trial is for 33 adults aged 18 to 75 who have not had prior cancer treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute and Hospital
RECRUITINGTianjin, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.